ストックスクリーナーアプリを入手
7.36
5.29%
0.37
前日終値:
$6.99
開ける：
$7.15
24時間の取引高:
14.28M
Relative Volume:
0.87
時価総額：
$7.71B
収益：
$140.98M
当期純損益:
$-854.60M
株価収益率:
-8.6183
EPS:
-0.854
ネットキャッシュフロー:
$-299.31M
1週間 パフォーマンス:
+2.22%
1か月 パフォーマンス:
-8.00%
6か月 パフォーマンス:
+252.15%
1年 パフォーマンス:
+159.15%
1日の値動き範囲:
$7.03
$7.455
1週間の範囲:
$6.685
$7.455
52週間の値動き範囲:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.36 | 7.71B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller - Insider Monkey
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IMMP) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
ImmunityBio, Inc. (NASDAQ:IBRX): Are Analysts Optimistic? - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - ACCESS Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
ImmunityBio | 4: Statement of changes in beneficial ownership of securities-Director Selecky Christobel - Moomoo
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026 - Insider Monkey
ImmunityBio (IBRX) director awarded 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director granted 65,600 stock options at $7.25 strike - Stock Titan
Director at ImmunityBio (NASDAQ: IBRX) awarded 65,600 options - Stock Titan
ImmunityBio (IBRX) re-elects full board, ratifies Deloitte as 2026 auditor - Stock Titan
2026-06-09 | Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | NDAQ:IMMP | Press Release - Stockhouse
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
FDA to Review Expanded Use of Cancer Drug - Los Angeles Business Journal
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend - Stocktwits
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc.: Shareholders Board Members Managers and Company Profile | US45256X1037 - marketscreener.com
ImmunityBio Inc Cash Flow – XETR:26CA - TradingView
ImmunityBio director Simon Barry J. sells $165,305 in stock - Investing.com UK
Director Barry Simon Sells 23,033 Shares of ImmunityBio Inc (IBR - GuruFocus
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny - Investing.com
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now - Yahoo Finance
ImmunityBio director Simon Barry J. sells $165,305 in stock By Investing.com - Investing.com India
ImmunityBio (IBRX) director Simon sells 23,033 shares under Rule 10b5-1 plan - Stock Titan
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio responds to FDA promotional compliance concerns - Investing.com
ImmunityBio stock rises after FDA compliance response - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors - TipRanks
IBRX: ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications - TradingView
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook - Yahoo Finance
D Boral Capital maintains ImmunityBio (IBRX) buy recommendation - MSN
ImmunityBio Inc stock (US45258J1025): HC Wainwright reiteration follows Nasdaq pullback - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Investors to Inquire about Securities Investigation - ACCESS Newswire
IBRX Reiterates by HC Wainwright -- Price Target Maintained at $15 - GuruFocus
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):